When added to first-line chemotherapy, lestaurtinib did not improve five-year OS and five-year relapse-free survival (RFS) in AML patients with confirmed FLT3-activating mutations, as shown by the meta-analyzed outcome data from United Kingdom Medical Research Council 15 (UK AML15) and 17 (UK AML17) trials [56]. This evidence concerns the gene FLT3 and acute myeloid leukemia.